885271-22-7 Usage
Uses
Used in Pharmaceutical Industry:
(5-FLUORO-1H-INDAZOL-3-YL)-ACETIC ACID is used as a research compound for its potential pharmacological activities, such as anti-inflammatory, analgesic, and anticancer properties. Its unique structure and reactivity contribute to its potential as a promising candidate for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
(5-FLUORO-1H-INDAZOL-3-YL)-ACETIC ACID is used as a starting material or intermediate in the synthesis of various pharmaceutical compounds. Its structural properties and potential pharmacological activities make it an interesting compound for further research and development in the field of medicinal chemistry.
Used in Drug Discovery and Development:
(5-FLUORO-1H-INDAZOL-3-YL)-ACETIC ACID is used as a lead compound in drug discovery and development processes. Its potential therapeutic properties and structural characteristics make it a valuable tool for identifying and optimizing new drug candidates with improved efficacy and safety profiles.
Used in Chemical Synthesis:
(5-FLUORO-1H-INDAZOL-3-YL)-ACETIC ACID is used as a building block in the synthesis of more complex organic compounds and pharmaceutical agents. Its reactivity and structural features make it a versatile component in the development of novel chemical entities with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 885271-22-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 1 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 885271-22:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*1)+(2*2)+(1*2)=197
197 % 10 = 7
So 885271-22-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H7FN2O2/c10-5-2-1-3-6-9(5)7(12-11-6)4-8(13)14/h1-3H,4H2,(H,11,12)(H,13,14)
885271-22-7Relevant academic research and scientific papers
NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS
-
Paragraph 0111, (2014/11/13)
The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS
-
Paragraph 0240, (2014/10/16)
The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
